Angiolab, Inc. (XKON:251280)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,060.00
+10.00 (0.20%)
Last updated: May 12, 2025
-12.76%
Market Cap 15.10B
Revenue n/a
Net Income n/a
Shares Out 2.99M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 291
Average Volume 1,020
Open 5,240.00
Previous Close 5,050.00
Day's Range 5,060.00 - 5,240.00
52-Week Range 5,030.00 - 9,200.00
Beta 0.24
RSI 27.93
Earnings Date n/a

About Angiolab

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 251280
Full Company Profile

News

There is no news available yet.